NYSE:EBS - Emergent Biosolutions Stock Price, Forecast & News

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent Biosolutions declared that its board has initiated a share buyback plan on Friday, March 23rd 2018, which allows the company to buyback $50,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board believes its shares are undervalued.

Emergent Biosolutions Inc (NYSE:EBS) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported $1.21 EPS for the quarter, topping the Zacks' consensus estimate of $0.63 by $0.58. The biopharmaceutical company earned $311.80 million during the quarter, compared to analyst estimates of $289.16 million. Emergent Biosolutions had a return on equity of 10.05% and a net margin of 0.42%. The company's revenue for the quarter was up 79.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.55 earnings per share. View Emergent Biosolutions' Earnings History.

Emergent Biosolutions updated its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.175-1.275 billion, compared to the consensus revenue estimate of $1.23 billion.

6 analysts have issued 12 month target prices for Emergent Biosolutions' stock. Their forecasts range from $64.00 to $75.00. On average, they expect Emergent Biosolutions' share price to reach $69.00 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.

News articles about EBS stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Emergent Biosolutions earned a news impact score of 2.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Emergent Biosolutions.

Emergent Biosolutions saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,610,000 shares, an increase of 6.5% from the January 15th total of 2,450,000 shares. Based on an average daily trading volume, of 307,300 shares, the days-to-cover ratio is presently 8.5 days. Approximately 6.1% of the company's stock are short sold. View Emergent Biosolutions' Current Options Chain.

Some companies that are related to Emergent Biosolutions include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Broadcom (AVGO), Global Payments (GPN), Netflix (NFLX), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), NXP Semiconductors (NXPI), CalAmp (CAMP) and Gentherm (THRM).

Emergent Biosolutions' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.00%), Earnest Partners LLC (3.94%), Goldman Sachs Group Inc. (2.18%), Rice Hall James & Associates LLC (2.13%), Renaissance Technologies LLC (1.48%) and Jennison Associates LLC (1.24%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

EBS stock was sold by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Renaissance Technologies LLC, Tygh Capital Management Inc., Marshall Wace LLP, Rice Hall James & Associates LLC, Mutual of America Capital Management LLC, UBS Group AG and Bank of America Corp DE. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Kathryn C Zoon, Sue Bailey and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.

EBS stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Earnest Partners LLC, Eaton Vance Management, State Street Corp, Loomis Sayles & Co. L P, Goldman Sachs Group Inc., FMR LLC and Prudential Financial Inc.. View Insider Buying and Selling for Emergent Biosolutions.

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EBS stock can currently be purchased for approximately $64.58.

Emergent Biosolutions has a market capitalization of $3.33 billion and generates $782.40 million in revenue each year. The biopharmaceutical company earns $62.70 million in net income (profit) each year or $2.33 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.View Additional Information About Emergent Biosolutions.

The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com/.

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]